Genentech's Lucentis BLA Will Not Include Data Supporting Dosing Advantage
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA denies fast-track designation for the wet age-related macular degeneration product; the company plans to keep the filing on track and submit the more flexible dosing data from its PIER trial in an sBLA.
You may also be interested in...
Genentech's Lucentis Heads to FDA
Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.
Genentech's Lucentis Heads to FDA
Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.
Pfizer/Eyetech Sets Sights On Diabetic Macular Edema For Macugen Sales Growth
Eyetech and Pfizer will initiate a Phase II/III pivotal trial during the second half of the year, Eyetech said. The age-related macular degeneration market, for which Macugen is currently approved, may face increasing competition